Riyadh - Mubasher: Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) generated a net profit of SAR 137.63 million for the second quarter (Q2) of 2026, a 4.25% increase from SAR 132.02 million in the prior-year period.
The pharmaceutical manufacturer’s revenue climbed by 12.39% to SAR 445.31 million, driven by strong demand in the Gulf and North Africa regions and high sales volumes in the ophthalmology and dermatology segments.
Gross profit for the quarter rose by 17.09% to SAR 293.65 million, though net earnings were tempered by rising selling and distribution costs and lower income from joint ventures.
For the first half (H1) of 2026, net profit reached SAR 305.84 million, up 5.81% year-on-year (YoY), on total revenues of SAR 926.70 million.
Earnings per share (EPS) for H1-26 amounted to SAR 4.37 when compared to SAR 4.13 a year earlier.
The company’s board declared an interim dividend of SAR 2.20 per share for H1-26, representing a 50% payout ratio.
Management noted that momentum recovered in the second quarter following a market contraction earlier in the year, with EBITDA margins for the first half holding at 37.30%.
Total shareholders’ equity stood at SAR 1.88 billion as of 30 June 2026.
In Q1-26, Jamjoom Pharma registered 7.11% YoY higher net profits at SAR 168.21 million, compared with SAR 157.03 million.
